Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Omega Therapeutics, Inc. OMGA
$8.92
+$0.77 (8.65%)
На 18:04, 12 мая 2023
+23.32%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
461093578.00000000
-
week52high
11.98
-
week52low
1.98
-
Revenue
2073000
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-2.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 04:00
Описание компании
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Wedbush | Outperform | 24 авг 2021 г. | |
| Piper Sandler | Overweight | 24 авг 2021 г. | |
| Jefferies | Buy | 24 авг 2021 г. | |
| Chardan Capital | Buy | 23 сент 2022 г. | |
| HC Wainwright & Co. | Buy | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Young Richard A | D | 764118 | 20000 | 10 янв 2023 г. |
| Karande Mahesh | A | 170000 | 170000 | 27 окт 2022 г. |
| Zeng Ling | A | 55000 | 55000 | 27 окт 2022 г. |
| McCauley Thomas | A | 55000 | 55000 | 27 окт 2022 г. |
| Reed Joshua | A | 55000 | 55000 | 27 окт 2022 г. |
| Moore Yan | A | 55000 | 55000 | 27 окт 2022 г. |
| McManus Kevin | A | 55000 | 55000 | 27 окт 2022 г. |
| Young Richard A | D | 784118 | 10000 | 14 сент 2022 г. |
| Boehm Rainer J. | A | 36713 | 36713 | 31 авг 2022 г. |
| Young Richard A | A | 18118 | 18118 | 08 июн 2022 г. |
Новостная лента
Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
GlobeNewsWire
17 янв 2023 г. в 07:00
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it will present a trial-in-progress poster at the upcoming American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., and virtually, January 19–21, 2023. The poster will highlight the design of the ongoing MYCHELANGELO™ I study, a Phase 1/2 open-label trial evaluating OTX-2002, a first-in-class Omega Epigenomic Controller™ (OEC) candidate, for the treatment of hepatocellular carcinoma (HCC) and other solid tumor types known for association with the c-Myc (MYC) oncogene.
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
PRNewsWire
26 сент 2022 г. в 07:00
CAMBRIDGE, Mass. , Sept. 26, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today announced that members of management will participate in two upcoming investor conferences.
Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
PRNewsWire
23 июн 2022 г. в 07:06
CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002, the Company's lead candidate for the treatment of hepatocellular carcinoma (HCC), at the upcoming European Society of Medical Oncology (ESMO) 2022 World Congress on Gastrointestinal (GI) Cancer, taking place in Barcelona, Spain, June 29 - July 2, 2022.
Omega Therapeutics, Inc. (OMGA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
20 мая 2022 г. в 13:32
Omega Therapeutics, Inc. (OMGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.